Page 95 - 《中国药房》2026年9期

联用；对于其他DOACs与三唑类抗真菌药的联用方案， Reporting System[J]. Int J Med Sci，2013，10（7）：796-803.
也应密切监测出血相关表现并及时调整抗凝或抗真菌 [10] NORÉN G N，SUNDBERG R，BATE A，et al. A statistical
治疗方案。 methodology for drug-drug interaction surveillance[J].
参考文献 Stat Med，2008，27（16）：3057-3070.
[11] THAKRAR B T，GRUNDSCHOBER S B，DOESSEGGER
[ 1 ] JOGLAR J A，CHUNG M K，ARMBRUSTER A L，et al.
L. Detecting signals of drug-drug interactions in a sponta‐
2023 ACC/AHA/ACCP/HRS guideline for the diagnosis
neous reports database[J]. Br J Clin Pharmacol，2007，64
and management of atrial fibrillation：a report of the
（4）：489-495.
American College of Cardiology/American Heart Associa‐
[12] NOGUCHI Y，TACHI T，TERAMACHI H. Review of sta‐
tion Joint Committee on clinical practice guidelines[J]. J
tistical methodologies for detecting drug-drug interactions
Am Coll Cardiol，2024，83（1）：109-279.
using spontaneous reporting systems[J]. Front Pharmacol，
[ 2 ] 周强，臧月月，陶瑛瑛，等. 新型口服抗凝药对比华法林
2019，10：1319.
用于左心室血栓有效性和安全性的 Meta 分析[J]. 中国
[13] LIU M，LIU W W，JIAO H M. Spontaneous hemothorax
药房，2022，33（24）：3034-3039.
caused by concomitant low-dose rivaroxaban and itracona-
[ 3 ] FERRI N，COLOMBO E，TENCONI M，et al. Drug-drug
zole in a 95-year-old patient：case report and literature
interactions of direct oral anticoagulants （DOACs）：from
review[J]. J Int Med Res，2021，49（9）：03000605211047712.
pharmacological to clinical practice[J]. Pharmaceutics，
[14] HOLT A，STRANGE J E，RASMUSSEN P V，et al. Blee-
2022，14（6）：1120.
ding risk following systemic fluconazole or topical azoles
[ 4 ] BRÜGGEMANN R J M，ALFFENAAR J C，BLIJLEVENS
in patients with atrial fibrillation on apixaban，rivaroxa‐
N M A，et al. Clinical relevance of the pharmacokinetic in‐
ban，or dabigatran[J]. Am J Med，2022，135（5）：595-
teractions of azole antifungal drugs with other coadminis‐
602.e5.
tered agents[J]. Clin Infect Dis，2009，48（10）：1441-1458.
[15] CHANG S H，CHOU I J，YEH Y H，et al. Association be‐
[ 5 ] WIGGINS B S，DIXON D L，NEYENS R R，et al. Select
tween use of non-vitamin K oral anticoagulants with and
drug-drug interactions with direct oral anticoagulants
without concurrent medications and risk of major bleeding
JACC review topic of the week[J]. J Am Coll Cardiol，
in nonvalvular atrial fibrillation[J]. JAMA，2017，318
2020，75（11）：1341-1350.
（13）：1250-1259.
[ 6 ] 彭文星. 口服抗凝药物治疗管理路径专家共识[J]. 临床
[16] SVALASTOGA M，LARSEN T L，BREKKE J，et al. Ef‐
药物治疗杂志，2024，22（9）：1-23.
fect of drug interactions with apixaban on clinical out‐
[ 7 ] STEFFEL J，COLLINS R，ANTZ M，et al. 2021 European
comes in cancer patients with venous thromboembolism
heart rhythm association practical guide on the use of non-
[J]. Front Oncol，2025，15：1520725.
vitamin K antagonist oral anticoagulants in patients with
[17] AOKI N，ABE K，TOKUTOMI H，et al. Characteristics of
atrial fibrillation[J]. Europace，2021，23（10）：1612-1676.
gastrointestinal bleeding while taking direct oral anticoagu-
[ 8 ] LI A，LI M K，CROWTHER M，et al. Drug-drug interac‐
lants in patients with nonvalvular atrial fibrillation and
tions with direct oral anticoagulants associated with ad‐
differences among drugs：a single-center retrospective
verse events in the real world：a systematic review[J].
cohort study[J]. J Clin Med，2025，14（1）：95.
Thromb Res，2020，194：240-245.
（收稿日期：2026-01-23 修回日期：2026-03-27）
[ 9 ] SAKAEDA T，TAMON A，KADOYAMA K，et al. Data
（编辑：舒安琴）
mining of the public version of the FDA Adverse Event

中国药房 2026年第37卷第9期 China Pharmacy 2026 Vol. 37 No. 9 · 1189 ·